8-KLeadership ChangesExhibits & Filings

AGILENT TECHNOLOGIES, INC. 8-K Report, Executive Changes (Jul 19, 2017)

Filed July 19, 2017For Securities:A

Summary

Agilent Technologies, Inc. announced a change to its Board of Directors, appointing Hans E. Bishop as a new member. The size of the Board has been increased from 10 to 11 directors to accommodate this appointment, which is effective as of July 18, 2017. Mr. Bishop will serve on both the Compensation Committee and the Nominating/Corporate Governance Committee, bringing a wealth of experience in leadership roles within the life sciences and medical device industries. Mr. Bishop's extensive background includes serving as President and CEO of Juno Therapeutics, Inc., and prior leadership positions at companies like Photothera Inc., Dendreon Corporation, and Bayer Healthcare Pharmaceuticals Inc. His appointment is expected to contribute valuable strategic insights to Agilent's governance and operations. The company stated that Mr. Bishop meets all independence requirements and has no undisclosed arrangements or material interests related to his appointment.

Key Highlights

  • 1Agilent Technologies appointed Hans E. Bishop to its Board of Directors.
  • 2The Board's size was increased from 10 to 11 members.
  • 3Mr. Bishop's appointment is effective July 18, 2017.
  • 4He will serve on the Compensation Committee and Nominating/Corporate Governance Committee.
  • 5Mr. Bishop brings significant executive experience from companies like Juno Therapeutics, Dendreon, and Bayer Healthcare.
  • 6The Board has confirmed Mr. Bishop meets all independence standards.
  • 7He will receive standard compensation for non-employee directors, prorated for the current year.

Frequently Asked Questions

Hans E. Bishop is a 52-year-old executive with extensive experience in the life sciences and medical device sectors. He most recently served as President and CEO of Juno Therapeutics, Inc. Prior to that, he held leadership roles at Photothera Inc., Dendreon Corporation, and Bayer Healthcare Pharmaceuticals Inc., where he managed significant product portfolios.

Increasing the Board size from 10 to 11 members was done to accommodate the appointment of the new director, Hans E. Bishop. This allows the company to bring in new expertise and perspectives without disrupting the existing board structure.

Mr. Bishop has been appointed to serve on two key committees of the Board: the Compensation Committee and the Nominating/Corporate Governance Committee. These committees play crucial roles in overseeing executive pay, board composition, and corporate governance practices.

Mr. Bishop will receive the standard compensation package provided to Agilent's non-employee directors. This compensation will be prorated to reflect the portion of the current year he serves on the Board. He will also enter into a standard indemnification agreement.